Introduction
Approximately 5-10% of all breast and ovarian cancers are hereditary. Germline mutations in the BRCA1 and BRCA2 genes are observed in about 25% of the cases of hereditary breast and ovarian cancer (HBOC) worldwide [1] . In Indian patients, a compilation of 5 studies of patients with positive family history of breast and ovarian cancer (294 probands) in whom both BRCA1 and 2 genes were analyzed, mutations were detected in either of the genes in 63 probands (21.4%) -a figure very similar to the studies in western countries [2] [3] [4] [5] [6] . Mutations in other genes such as TP53, PTEN, ATM and STK11 were found in less than 5% of HBOC cases [7] . Several recent experimental and clinical reports [8] [9] [10] [11] support the role of genes of the MRN complex in susceptibility to HBOC. Nextgeneration sequencing (NGS) technologies have helped understand the role of MRN genes in determining breast cancer susceptibility as it allows screening of multiple genes in a cost-effective manner. We present a female breast cancer patient (50-year-old at presentation) with a positive family history of cancer who underwent NGSbased gene panel testing, and in whom a pathogenic mutation in 1 of the intermediate penetrance genes, MRE11A, was identified. 
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Case Report
The index patient was a 60-year-old female (supplementary fig. 1 , www. karger.com/?DOI=457786; III-5) of Indian Asian origin. At the age of 50 years, she was diagnosed with breast carcinoma. 1 of the proband's sisters was diagnosed with breast cancer at 60 years (III-1). The other sister (58 years old; III-3) and the younger brother (55 years old; III-7) are both healthy. The proband's mother (II-1) died at the age of 77 of endometrial cancer. A maternal aunt (79 years, II-5) died of breast cancer. Based on the family history of 3 cases of breast cancer, HBOC was diagnosed. Sanger sequencing and MLPA (MRC Holland) for BRCA genes were performed using genomic DNA extracted from blood leukocytes [12] . No mutation was identified in the BRCA genes. NGSbased panel testing for 21 known breast cancer susceptibility genes (list of genes available on request) on a high-throughput platform was done at the BGI Clinical Laboratories (Shenzhen, China). A pathogenic heterozygous mutation c.1090C>T (p.Arg364Ter) in the MRE11A gene was detected [13, 14] . This mutation was confirmed in the index patient by Sanger sequencing (supplementary fig. A ; www.karger.com/?DOI=457786). A 308-bp DNA fragment spanning exon 10 was amplified and cut with Rsa1 restriction enzyme (New England BioLabs) at 37 ° C for 4 h. The wild-type sequence was cut into 3 fragments of 158, 86 and 64 bp. The mutation eliminates 1 of the restriction site and Rsa 1 enzyme cuts the mutated amplicon into 2 fragments of 222 and 86 bp. Samples from family members of the proband and 100 normal controls were subjected to restriction fragment length polymorphism analysis (supplementary fig. B www.karger.com/?DOI=457786), which showed an absence of mutation in the 100 normal controls.
Clinical Management of Mutation Carriers
Two sisters (1 affected, III-1; 1 unaffected, III-3) of the index patient tested positive and 1 niece (IV-3) tested negative for the mutation. No recommended guidelines are yet available for carriers of a mutation in the MRE11 gene. Regular self and clinical breast cancer examination and screening with annual magnetic resonance imaging and mammography was advised. Although there is no reported evidence of benefits of prophylactic bilateral salpingo-oopherectomy in MRE11 gene mutation carriers, the proband's sister (III-3) made an informed decision to undergo prophylactic oopherectomy.
Discussion
A previously reported, pathogenic, heterozygous mutation c.1090C>T (p.Arg364Ter) in the MRE11A gene was detected in this case [13, 14] . The MRE11A protein is a component of the MRN (MRE11A/RAD50/NBS1) complex, which is part of the BRCA1-associated genome surveillance complex (BASC). In response to DNA double-strand breaks (DSB), the MRN complex serves as the sensor of DNA breakage, and activates the key signal transducer of the DNA damage response machinery [15, 16] . The wild-type 70-kDa MRE11A protein is highly conserved across species. The C to T change at position 1,090 of the gene results in the termination of the MRE11A protein after 363 amino acids. The truncated protein lacks 2 DNA-binding domains, the GAR domain and the RAD50 binding site, and a few amino acids from the C-terminal region of capping site (supplementary fig. 2 , www.karger.com/?DOI=457786). The mutated protein is not able to interact with RAD50 and form the MRN core complex. Single-and double-stranded (ds) DNA endonuclease, and a 3'-5' dsDNA exonuclease activity of the phosphoesterase domain of MRE11 A protein is also integral to the DNA DSB repair mechanism [17] . The absence of DSB repair results in an accumulation of genomic instability, leading to increased susceptibility to cancer. Potentially pathogenic germline mutations have been reported in MRN complex genes in a number of studies in families with an hereditary predisposition to breast and ovarian cancer [10, 11, [18] [19] [20] [21] . Heikkinen et al. [21] reported a mutation in the MRE11 gene (p.R305W) in a family with ovarian and cervical cancer in a study of 151 HBOC families. Absence of mutation in 1,000 controls confirmed its role in increasing susceptibility to breast cancer. Another study described mutations in 3 out of 708 consecutive breast cancer patients. A deletion causing a splice site defect in the MRE11A gene was found in a patient with serous ovarian carcinoma in a study of 273 women with ovarian carcinoma [18] . Although these reports provided evidence that mutations in MRE11 increase breast cancer risk, the tumorigenic contribution of MRN genes in breast cancer formation needs to be evaluated.
Hsu et al. [9] reported that the association of cancer risk with high-risk MRN genotypes is stronger in women who are more susceptible to estrogen exposure, i.e. those older than > 26 years of age at first full-term pregnancy (FTP) than those with fewer FTPs and no history of breast feeding. The suggested mechanism is that the estrogen metabolites bind to DNA and initiate DSB formation, and cells with defective MRN-mediated DSB repair are more susceptible to cancer formation. In the present case, the proband's mother and her sister had their first FTP before the age of 26 years and had more FTPs compare to affected daughters (supplementary fig. 1 , www.karger.com/?DOI=457786). The proband and her sister developed breast cancer at 50 and 60 years of age, respectively, while their mother and her sister developed endometrial cancer (77 years) and breast cancer (79 years), respectively, at a later age. This observation supports the hypothesis given by Hsu et al. [9] that the breast cancer risk due to high-risk MRN genotypes can be modified by reproductive factors. The proband's mother died at 77 years of endometrial cancer. This case and other studies highlight the association of mutations in the MRE11A gene with endometrial cancer [22] [23] [24] . Koppensteiner et al. [23] demonstrated that endometrial cancer associated with MRE11 mutation has higher sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitor therapy. PARP inhibitors are effective against tumors with deficient DNA repair mechanisms, and recent reports provide evidence that MRE11 mutations can serve as a predictive biomarker for the efficacy of PARP inhibitors.
In conclusion, the management of subjects with mutations in genes other than BRCA is a challenge in the clinic, as no recommended guidelines are yet available for such individuals. The level of associated cancer risk needs to be determined in larger number of patients with adequate follow-up to define appropriate management guidelines. The identification of mutations in non-BRCA susceptibility genes will provide a better understanding of genetic heterogeneity in high-risk families.
